CorMedix
CRMD • NASDAQ
CorMedix is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Joseph Todisco, with a market cap of $531.2M.
CEOJoseph Todisco
Next Earnings
Upcoming earnings announcement for CorMedix
Date
Tuesday, May 5, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.34
Revenue Estimate
$106.6M
Earnings History
Past 12 earnings reports for CorMedix
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | $0.61Est: $0.83 | -26.5% | $128.6MEst: $127.1M | +1.2% |  10-K |
| Nov 12, 2025 | Q3 2025 | $0.57Est: $0.57 | 0.0% | $104.3MEst: $86.0M | +21.2% | 10-Q |
| Aug 7, 2025 | Q2 2025 | $0.28Est: $0.19 | +47.4% | $39.7MEst: $36.3M | +9.5% | 10-Q |
| May 6, 2025 | Q1 2025 | $0.30Est: $0.25 | +20.0% | $39.1MEst: $36.0M | +8.6% | 10-Q |
| Mar 25, 2025 | Q4 2024 | $0.22Est: $0.14 | +57.1% | $31.2MEst: $28.3M | +10.1% | 10-K |
| Oct 30, 2024 | Q3 2024 | -$0.05Est: -$0.10 | +50.0% | $11.5MEst: $10.8M | +5.7% | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.25Est: -$0.25 | 0.0% | $806.1KEst: $1.7M | -51.7% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.25Est: -$0.28 | +10.7% | - | — | 10-Q |
| Mar 12, 2024 | Q4 2023 | -$0.26Est: -$0.20 | -30.0% | -Est: -$250.0K | +100.0% | 10-K |
| Nov 14, 2023 | Q3 2023 | -$0.17Est: -$0.21 | +19.0% | - | — | — |
| Aug 8, 2023 | Q2 2023 | -$0.25Est: -$0.24 | -4.2% | - | — | 10-Q |
| May 15, 2023 | Q1 2023 | -$0.24Est: -$0.20 | -20.0% | - | — | — |